Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 66.9% during the 4th quarter, according to its most recent filing with the SEC. The institutional investor owned 9,858 shares of the medical research company’s stock after selling 19,911 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Charles River Laboratories International were worth $2,330,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. Regency Capital Management Inc. DE acquired a new stake in shares of Charles River Laboratories International during the fourth quarter valued at about $3,703,000. WCM Investment Management LLC acquired a new stake in Charles River Laboratories International during the 4th quarter valued at approximately $1,396,000. DekaBank Deutsche Girozentrale increased its holdings in Charles River Laboratories International by 98.6% during the 4th quarter. DekaBank Deutsche Girozentrale now owns 14,094 shares of the medical research company’s stock worth $3,333,000 after purchasing an additional 6,997 shares during the last quarter. AMG National Trust Bank purchased a new stake in Charles River Laboratories International during the 3rd quarter worth approximately $1,119,000. Finally, DAVENPORT & Co LLC acquired a new position in shares of Charles River Laboratories International in the 4th quarter valued at approximately $1,904,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of research analyst reports. Citigroup lifted their price target on shares of Charles River Laboratories International from $215.00 to $250.00 and gave the stock a “neutral” rating in a research note on Thursday, February 15th. Robert W. Baird increased their price target on shares of Charles River Laboratories International from $252.00 to $268.00 and gave the stock an “outperform” rating in a research report on Thursday, February 15th. UBS Group lifted their price target on Charles River Laboratories International from $270.00 to $290.00 and gave the stock a “buy” rating in a research note on Thursday, February 15th. TheStreet upgraded Charles River Laboratories International from a “c+” rating to a “b-” rating in a research note on Friday, March 1st. Finally, Evercore ISI lifted their target price on Charles River Laboratories International from $260.00 to $265.00 and gave the stock an “outperform” rating in a research report on Thursday, February 15th. Five equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.23.

Insider Buying and Selling at Charles River Laboratories International

In other news, EVP Victoria L. Creamer sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total value of $1,268,500.00. Following the completion of the sale, the executive vice president now directly owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the sale, the executive vice president now owns 13,550 shares of the company’s stock, valued at approximately $3,437,635. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Shannon M. Parisotto sold 5,882 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $241.20, for a total value of $1,418,738.40. Following the transaction, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 14,932 shares of company stock valued at $3,693,663. Company insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

CRL stock opened at $239.98 on Wednesday. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The stock has a market capitalization of $12.36 billion, a price-to-earnings ratio of 26.06, a PEG ratio of 1.78 and a beta of 1.40. The company has a debt-to-equity ratio of 0.73, a quick ratio of 1.16 and a current ratio of 1.52. The stock’s fifty day moving average is $254.27 and its two-hundred day moving average is $222.23.

Charles River Laboratories International (NYSE:CRL) last released its quarterly earnings results on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating analysts’ consensus estimates of $2.39 by $0.07. Charles River Laboratories International had a return on equity of 16.53% and a net margin of 11.49%. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $991.25 million. During the same quarter in the previous year, the company posted $2.98 earnings per share. The business’s revenue for the quarter was down 7.9% compared to the same quarter last year. On average, research analysts predict that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).